



RECEIVED

JUL 11 2003

TECH CENTER 1600/2900

#9
DP
7/13/03

Practitioner's Docket No. MPI96-031CP1DV1CPACN1M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Chen, Zhijian J.		
Application No.:	10/052,005	Group No.:	1652
Filed:	January 17, 2002	Examiner:	Patterson, Charles L., Jr.
For:	A UBIQUITIN-DEPENDENT KINASE CAPABLE OF SITE-SPECIFIC PHOSPHORYLATION OF IKB-A		

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

**IDENTIFICATION OF TIME OF FILING THE ACCOMPANYING
INFORMATION DISCLOSURE STATEMENT**

The information disclosure statement submitted herewith is being filed:

Within three months of the filing date of the application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 C.F.R. section 1.97(b).

OR

After three months of the filing date of this national application or the date of entry of the national

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Mail Stop DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail.

as "Express Mail Post Office to Address" Mailing Label No.

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.


Signature

Sean Hunziker

(type or print name of person certifying)

Date: July 7, 2003

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. MPI96-031CP1DV1CPACN1M

stage as set forth in Section 1.491 in an international application or after the mailing date of the first Office action on the merits, whichever event occurred last but *before* the mailing date of either:

- (1) a final action under Section 1.113,
- (2) a notice of allowance under Section 1.311, or
- (3) an action that otherwise closes prosecution in the application

whichever occurs first.

Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

OR

The information disclosure statement transmitted herewith is being filed *after* a final action under Section 1.113, or a notice of allowance under Section 1.311, whichever occurs first, but before, or simultaneously with, the payment of the issue fee.

In accordance with the requirements of 37 C.F.R. Section 1.97(d):

A. Accompanying this transmittal is the fee set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c). (\$180.00).

B. Each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(1).

C. No item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application and to the knowledge of the person signing the statement after making reasonable inquiry, was known to any individual designated in Section 1.56(c) more than three months prior to the filing of the information disclosure statement. 37 C.F.R. Section 1.97(e)(2).

Practitioner's Docket No. MPI96-031CP1DV1CPACN1M

FEE PAYMENT

3. The fee due is set forth in 37 C.F.R. Section 1.17(p) for submission of an information disclosure statement under Section 1.97(c) (\$180.00).

Applicant believes no fee is due in connection with this submission.

	Fee due	\$180.00
--	---------	----------

METHOD OF PAYMENT OF FEE

4. Attached is a check in the amount of \$_____.

<input checked="" type="checkbox"/> Charge Account No. 501668 in the amount of	\$180.00	.
--	----------	---

A duplicate of this request is attached.

If any additional fees are due, please charge Account 501668.

<u>July 7, 2003</u>	MILLENNIUM PHARMACEUTICALS, INC. By <u>Tracy M. Sioussat</u> Tracy M. Sioussat Registration No. 50,609 75 Sidney Street Cambridge, MA 02139 Telephone - 617-374-7679 Facsimile - 617-551-8820
---------------------	---


RECEIVED

Practitioner's Docket No. MPI96-031CP1DV1CPACN1M

PATENT 11 2003

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/200



In re application of: Chen, Zhijian J.
Application No.: 10/052,005 Group No.: 1652
Filed: January 17, 2002 Examiner: Patterson, Charles L., Jr.
For: A UBIQUITIN-DEPENDENT KINASE CAPABLE OF SITE-SPECIFIC
PHOSPHORYLATION OF IKB-A

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

List of Sections Forming Part of This Information Disclosure Statement

The following sections are being submitted for this Information Disclosure Statement:

1. Preliminary Statements
2. Form PTO/SB/08B (substitute for Form PTO-1449)
3. Copies of Listed Information Items Accompanying This Statement
4. Identification of Person(s) Making This Information Disclosure Statement

Section 1. Preliminary statements

Applicants submit herewith patents, publications or other information, of which they are aware that they believe may be material to the examination of this application, and in respect of which, there may be a duty

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING

deposited with the United States Postal Service in an envelope addressed to the Mail Stop DD, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

with sufficient postage as first class mail.

as "Express Mail Post Office to Address"
Mailing Label No.

TRANSMISSION

transmitted by facsimile to the Patent and Trademark Office.


Signature

Sean Hunziker

(type or print name of person certifying)

Date: July 7, 2003

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. section 1.10(b). "Since the filing of correspondence under section 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

07/10/2003 CNGUYEN 00000154-501668 10052005
02 FC:18056 180.00 DA

Practitioner's Docket No. MPI96-031CP1DV1CPACN1M

to disclose.

The filing of this information disclosure statement shall not be construed as a representation that a search has been made (37 C.F.R. section 1.97(g)), an admission that the information cited is, or is considered to be, material to patentability, or that no other material information exists.

The filing of this information disclosure statement shall not be construed as an admission against interest in any manner. Notice of January 9, 1992, 1135 O.G. 13-25, at 25.

Section 2. Copies of Listed Information Items Accompanying This Statement

Legible copies of all items listed in Forms PTO/SB/08A and 08B (substitute for Form PTO-1449) accompany this information statement.

(complete the following, if applicable)

 Exception(s) to above:


 Items in prior application, from which an earlier filing date is claimed for this application, as identified in Section 4.

 Cumulative patents or publications identified in Section 5.

July 7, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By



Tracy M. Sioussat

Registration No. 50,609

75 Sidney Street

Cambridge, MA 02139

Telephone - 617-374-7679

Facsimile - 617-551-8820